Manufacturing & Pathogen Safety
Octapharma has pioneered a number of safety innovations that have set the standard for the protein products industry
Octagam 10% manufacturing and purification process1-3
Octagam 10% contains all 4 subclasses of IgG, with a percentage distribution equivalent to the one found in normal plasma
- Octagam 10% is made from large pools of donated plasma which go through a rigorous purification process for the inactivation and removal of viruses
- Other precautions against viral transmission include: selection of plasma donors, screening of donations and plasma pool, as well as final product testing for viruses
- Octagam 10% is manufactured by cold ethanol fractionation followed by ultrafiltration and chromatography. The manufacturing process includes treatment with a solvent/detergent, and incubation at low pH
Validated viral removal and inactivation3-5
The manufacturing process for octagam 10% has been validated for its capacity to remove and inactivate both enveloped and non-enveloped viruses
All units of human plasma used in the manufacture of octagam 10% liquid are collected in US-based Octapharma Plasma centers that are licensed by the US Food and Drug Administration (FDA). Plasma is tested by FDA-licensed serological tests for HBsAg, antibodies to HCV and HIV, and Nucleic Acid Test (NAT) for HCV and HIV-1 and found to be non-reactive (negative).
|Production Step||In vitro reduction factor [log10]|
|Enveloped Viruses||Non-Enveloped Viruses|
|Cold ethanol fractionation||≥ 4.81||≥ 6.28||≥ 7.13||≥ 7.13||≥ 6.53|
|S/D treatment||≥ 4.93||5.23||≥ 6.77||n.a.||n.a.|
|pH 4 treatment||≥ 4.33||≥ 6.71||6.71||5.07||< 1*|
|Global reduction factor||≥ 14.07||≥ 18.22||≥ 20.61||≥ 12.20||≥ 6.53|
*Not calculated for global LRF.
HIV-1: Human Immunodeficiency Virus-1; PRV: Pseudorabies Virus; SBV: Sindbis virus; MEV: mouse encephalomyelitis virus, PPV: porcine parvovirus
- Octagam 10% Full Prescribing Information. Paramus, NJ: Octapharma USA Inc; rev June 2021.
- Octapharma. Data on file.
- Buchacher A, Kaar W. Intravenous immunoglobin G from human plasma—purification concepts and important quality criteria. In: Bertolini J, Goss N, Curling J, eds. Production of Plasma Proteins for Therapeutic Use. Hoboken, NJ: John Wiley & Sons, Inc; 2013.
- Dichtelmüller HO, Biesert L, Fabbrizzi F, et al. Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection of Plasma Protein Therapeutics Association member companies. Transfusion. 2011;51(7):1412-1430.
- Dichtelmüller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection of Plasma Protein Therapeutics Association member companies. Transfusion. 2009;49(9):1931-1943.